Prosecution Insights
Prosecution Insights
5 pending office actions • 3 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 3 | 66.7% | +25.5% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +29.8% |
| BREDEFELD, RACHAEL EVA | 1 | 27.5% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18650053 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | HOWELL, THEODORE R | 77d |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 67d overdue |
| 18650053 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | HOWELL, THEODORE R | 77d |
| 19079284 | PHARMACEUTICAL COMPOSITIONS COMPRISING UNIFORM BLENDS OF REBOXETINE | YOUNG, MICAH PAUL | — |
| 18650022 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | HOWELL, THEODORE R | — |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1618 | 1 |
| 3786 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 67d overdue | Pending | Apr 03, 2025 |
| 19079284 | PHARMACEUTICAL COMPOSITIONS COMPRISING UNIFORM BLENDS OF REBOXETINE | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | — | Pending | Mar 13, 2025 |
| 18650022 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | HOWELL, THEODORE R | 1628 | DPOther | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18650053 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | HOWELL, THEODORE R | 1628 | §101DPOther | Non-Final OA | 77d | Pending | Apr 29, 2024 |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | 3786 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial